IBAB Ion Beam Applications SA

IBA to share long-term growth strategy at upcoming 2025 Capital Markets Day

IBA to share long-term growth strategy at upcoming 2025 Capital Markets Day



Louvain-la-Neuve, Belgium, 04 April, 2025 –  (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, will be hosting a Capital Markets Day (CMD) this coming Monday 7 April from 2pm to 5:00pm CEST (8am ET to 11:00am ET) at its headquarters in Louvain-la-Neuve, Belgium, and via live webcast.

At the event IBA’s management team will outline the company’s strategic roadmap and long-term growth ambitions. The agenda is outlined below:

  • Webcast open: 2pm
  • Purpose, Vision & Strategy​​
  • Business Review – Execution Plan & Opportunities​​
    • Industrial Solutions
    • RadioPharma Solutions
    • Engineering & Supply Chain
    • Proton Therapy
    • Dosimetry
    • New Ventures
  • Financials & Outlook
  • Webcast close: 5pm

To attend via webcast, register via this . Please complete the registration at least 15 minutes before the start of the event. No new material financial information will be delivered during the CMD.

The presentation will be made available on IBA’s website ahead of the event on and a recording will also be made available shortly afterwards on the same page and on .

For further information, please contact ICR Healthcare at .   

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:

CONTACTS

Olivier Lechien

Corporate Communication Director



ICR Healthcare

Amber Fennell, Angela Gray, Lucy Featherstone

+44 (0) 20 3709 5700

Attachment



EN
04/04/2025

Underlying

IBABIon Beam Applications SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

 PRESS RELEASE
Free
IBAB Ion Beam Applic...

IBA – TRANSPARENCY NOTIFICATION

IBA – TRANSPARENCY NOTIFICATION (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, September 10, 2025 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on September 3, 2025. In its notification, Marcel Jo Maschmeyer ind...

September 10, 2025 1 EN
 PRESS RELEASE
Free
IBAB Ion Beam Applic...

IBA SA – NOTIFICATION TRANSPARENCE

IBA SA – NOTIFICATION TRANSPARENCE (article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 10 septembre 2025, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce devoir effectuer une notification en matière de transparence conformément à l'article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes (« loi transparence »), à la suite d’une notification reçu...

September 10, 2025 1 EN
Michiel Declercq
  • Michiel Declercq
IBAB Ion Beam Applic...

IBA 1H25 Conference call feedback & model update

IBA reported good 1H25 results, with revenues up 40% to € 304.9m (kbcse: € 274.6m) driven by strong backlog conversion in PT as well as OA. However, as most of the conversion relates to legacy lower margin contracts in Spain and China, the gross profit increase of +27% to € 90.0m (kbcse: € 93.4m) and REBIT of € 10.6m (kbcse: € 10.3m) were broadly in line with our estimates. However net cash significantly deteriorated on the back of WC investments, as anticipated. We are pleased to see IBA reiter...

IBAB ION BEAM APPLICATIONS SA
08/28/25 August 28, 2025 1 EN
ING Helpdesk
  • ING Helpdesk
EURN EURONAV NV
CFEB Compagnie d'Ent... ... (+5)

REVISED VERSION - Benelux Morning Notes - updated to include IBA news

CFE: 1H results a bit light, FY outlook maintained. CMB.TECH: VLCC reasonable, pressure on Dry Bulk rates. dsm-firmenich: Givaudan CMD; Strategy 2030. Gimv: Investing in specialised healthcare services in the Netherlands. IBA: More sales but at lower margin

EURN EURONAV NV
CFEB COMPAGNIE D'ENTREPRISES CFE SA
GIMB GIMV NV
IBAB ION BEAM APPLICATIONS SA
DSFIR KONINKLIJKE DSM N.V.
08/28/25 August 28, 2025 1 EN
Hilde Van Boxstael ... (+6)
  • Hilde Van Boxstael
  • Kristof Samoy
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Wim Lewi
COMB COMPAGNIE DU BOIS SAUVAGE SA
EURN EURONAV NV
CFEB COMPAGNIE D'ENTREPRISES CFE SA
IMMO COMPAGNIE IMMOBILIERE DE BELGIQUE SA
IBAB ION BEAM APPLICATIONS SA
08/28/25 August 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch